Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $959,200.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $17.44, for a total transaction of $959,200.00. Following the transaction, the chief executive officer now owns 520,661 shares in the company, valued at approximately $9,080,327.84. This trade represents a 9.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.46, for a total value of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total value of $5,450.77.
• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.89, for a total value of $928,950.00.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total value of $30,479.04.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total transaction of $350,839.00.

Centessa Pharmaceuticals Price Performance

Shares of CNTA traded down $0.39 during trading hours on Friday, reaching $17.16. 791,268 shares of the company traded hands, compared to its average volume of 434,271. The stock has a fifty day simple moving average of $16.64 and a 200 day simple moving average of $13.57. Centessa Pharmaceuticals plc has a fifty-two week low of $6.65 and a fifty-two week high of $18.97. The stock has a market capitalization of $2.26 billion, a PE ratio of -11.22 and a beta of 1.52. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.05. As a group, research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on CNTA shares. BMO Capital Markets lifted their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a research report on Monday, September 16th. Morgan Stanley raised Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley initiated coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a "buy" rating and a $33.00 target price on the stock. Guggenheim raised their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group boosted their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock worth $40,000 after buying an additional 826 shares during the last quarter. Atria Investments Inc boosted its position in shares of Centessa Pharmaceuticals by 7.0% in the third quarter. Atria Investments Inc now owns 17,134 shares of the company's stock worth $274,000 after acquiring an additional 1,116 shares during the last quarter. GAMMA Investing LLC grew its holdings in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock valued at $48,000 after purchasing an additional 1,509 shares during the period. Quarry LP increased its position in Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company's stock worth $87,000 after purchasing an additional 3,108 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Centessa Pharmaceuticals by 99.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company's stock worth $217,000 after purchasing an additional 6,785 shares during the period. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.